Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Shenzhen Forward Pharmaceuticals Co. Limited has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are spread across 2 distinct art units, indicating a range of technical classifications for their pharmaceutical assets. The prosecution involves 3 distinct examiners, which means each of the active matters is being reviewed by a different individual.
REILLY, SOPHIA JANE is the busiest examiner for the company, currently managing 1 pending office action. This matter is part of the total pending office actions currently active for the portfolio. With multiple examiners and 2 distinct art units, the company's filings are subject to multiple viewpoints and administrative standards. This distribution suggests that the pending office actions are not concentrated under a single examiner, even though they all fall within the Biotechnology & Pharmaceuticals field. Practitioners must account for these varying examiner perspectives when managing the active docket.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838136 | QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR | REILLY, SOPHIA JANE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002578 | Salts of Compound and Pharmaceutical Compositions Containing the Same | HEITMEIER, KENDALL NICOLE | 23d |
| 18838136 | QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR | REILLY, SOPHIA JANE | — |
| 18259871 | Anti-FGFR2 Antibody and Use Thereof | PETERS, ALEC JON | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838136 | QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR | REILLY, SOPHIA JANE | — | §102§103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18259871 | Anti-FGFR2 Antibody and Use Thereof | PETERS, ALEC JON | 1641 | §112DP | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18002578 | Salts of Compound and Pharmaceutical Compositions Containing the Same | HEITMEIER, KENDALL NICOLE | 1621 | §103Other | Final Rejection | 23d | Pending | Dec 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial